Skip to content

Author

C. Mastroianni

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Long-term treatment durability and safety after switching to bictegravir/emtricitabine/tenofovir alafenamide in real-world practice: a 144-week update from the BICTEL cohort.

BACKGROUND Real-world evidence on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) beyond 96 weeks remains limited. We assessed treatment durability, tolerability and laboratory safety after switching to BIC/FTC/TAF through 144 weeks in routine HIV care. METHODS As of 30 March 2026, 180 participants enro...

Luca Bortolani, Riccardo Donà, Antonietta Impellizzeri et al. · 0 citations
Open access Sep 2026

The Triglyceride‐Glucose (TyG) Index and Incident Diabetes and Cardiovascular Events in People Living With HIV‐1 Infection. A 14‐Year Observational Cohort Study

The triglyceride‐glucose (TyG) index has shown predictive value for Type 2 diabetes mellitus (T2DM) and cardiovascular events (CVEs) in the general population, but its utility in PWH remains unclear.

Daniele Pastori, G. Gazzaniga, T. Brogi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.